<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03679949</url>
  </required_header>
  <id_info>
    <org_study_id>7647</org_study_id>
    <nct_id>NCT03679949</nct_id>
  </id_info>
  <brief_title>Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia</brief_title>
  <official_title>Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to assess the impact of cannabis on the analgesic and
      abuse-liability effects of a sub-threshold dose of a commonly used analgesic.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a randomized, cross-over, double-blind, placebo-controlled study. All participants will partake in each arm and receive all interventions.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Effects</measure>
    <time_frame>6 weeks</time_frame>
    <description>Participants will rate &quot;drug liking&quot;, &quot;good drug effects&quot;, and &quot;high&quot; on a visual analogue scale (VAS; 1-100mm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cold Pressor Test</measure>
    <time_frame>6 weeks</time_frame>
    <description>Participants will immerse their hand in a bucket of ice water to determine pain threshold and pain tolerance latencies (in seconds).</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Pain</condition>
  <condition>Abuse, Drug</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 0 mg oxycodone (oral) and placebo cannabis (vaporized)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2.5 mg oxycodone (oral) and placebo cannabis (vaporized)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabis (THC:CBD = ~1:0)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabis (THC:CBD = ~ 0:1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabis (THC:CBD = ~ 1:1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0 mg oxycodone (oral) and cannabis with equal CBD and THC concentrations (vaporized)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabis (THC:CBD = ~1:0) + Oxycodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2.5 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabis (THC:CBD = ~ 0:1) + Oxycodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2.5 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabis (THC:CBD = ~ 1:1) + Oxycodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2.5 mg oxycodone (oral) and cannabis with equal concentrations of THC and CBD (vaporized)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Oxycodone, 2.5 mg</description>
    <arm_group_label>Cannabis (THC:CBD = ~ 0:1) + Oxycodone</arm_group_label>
    <arm_group_label>Cannabis (THC:CBD = ~ 1:1) + Oxycodone</arm_group_label>
    <arm_group_label>Cannabis (THC:CBD = ~1:0) + Oxycodone</arm_group_label>
    <arm_group_label>Oxycodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis (THC:CBD = ~ 1:0)</intervention_name>
    <description>Cannabis with high THC concentration and negligible CBD concentrations</description>
    <arm_group_label>Cannabis (THC:CBD = ~1:0)</arm_group_label>
    <arm_group_label>Cannabis (THC:CBD = ~1:0) + Oxycodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis (THC:CBD = ~ 0:1)</intervention_name>
    <description>Cannabis with high CBD concentration and negligible THC concentrations</description>
    <arm_group_label>Cannabis (THC:CBD = ~ 0:1)</arm_group_label>
    <arm_group_label>Cannabis (THC:CBD = ~ 0:1) + Oxycodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis (THC:CBD = ~ 1:1)</intervention_name>
    <description>Cannabis with equivalent CBD and THC concentrations</description>
    <arm_group_label>Cannabis (THC:CBD = ~ 1:1)</arm_group_label>
    <arm_group_label>Cannabis (THC:CBD = ~ 1:1) + Oxycodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone</description>
    <arm_group_label>Cannabis (THC:CBD = ~ 0:1)</arm_group_label>
    <arm_group_label>Cannabis (THC:CBD = ~ 1:1)</arm_group_label>
    <arm_group_label>Cannabis (THC:CBD = ~1:0)</arm_group_label>
    <arm_group_label>Oxycodone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo cannabis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant female aged 21-53 years

          -  Previous cannabis use

          -  Previous opioid use

          -  Urine test positive for recent cannabis use

          -  Being able to perform all study procedures

          -  Currently practicing an effective form of birth control (women only)

        Exclusion Criteria:

          -  Meeting criteria for some Use Disorders

          -  Report regular illicit drug use

          -  If medical history, physical and psychiatric examination, or laboratory tests
             performed during the screening process revealed any significant illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>53 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline A Cooper, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Psychiatric Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline A Arout, PhD</last_name>
    <phone>646-774-6167</phone>
    <email>caroline.arout@nyspi.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ziva D Cooper, PhD</last_name>
    <phone>310-206-9942</phone>
    <email>zcooper@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline A Arout, PhD</last_name>
      <phone>646-774-6167</phone>
      <email>caroline.arout@nyspi.columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Caroline Arout</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <keyword>experimental pain</keyword>
  <keyword>Cannabis</keyword>
  <keyword>Cannabidiol</keyword>
  <keyword>THC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

